Clinical Trials
2.9k
Active:460
Completed:1177
Trial Phases
6 Phases
Early Phase 1:76
Phase 1:723
Phase 2:1007
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2392 trials with phase data)• Click on a phase to view related trials
Phase 2
1007 (42.1%)Phase 1
723 (30.2%)Not Applicable
455 (19.0%)Phase 3
102 (4.3%)Early Phase 1
76 (3.2%)Phase 4
29 (1.2%)Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Clear Cell CarcinomaPhase 1Growth Factor
- Interventions
- Drug: Lymphodepleting chemotherapyDrug: CyclophosphamateDrug: TGFBR-2 KO CD70 CAR NK
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07072234
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Not Applicable
Not yet recruiting
- Conditions
- Colorectal CancerRegorafenibHigh Risk Patients
- Interventions
- Drug: Regorafenib (CT)
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT07071961
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Not Applicable
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Oral Cladribine
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT07053020
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
Not Applicable
Not yet recruiting
- Conditions
- Pediatric Acute Leukemia
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT07052994
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
Not Applicable
Not yet recruiting
- Conditions
- Brain Metastases
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT07053033
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 577
- Next
News
No news found